Dear Wendy
Here is the copy of a study on venlafaxine. Hope this help.
Kindly
Françoise Railhet
Manager of the LLL France Medical Associates Program
[log in to unmask]


Distribution and excretion of venlafaxine and
O-desmethylvenlafaxine in human milk.


Ilett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, Groves
A, Yapp P. Department of Pharmacology, University of Western Australia,
Nedlands. Br J Clin Pharmacol 1998 May;45(5):459-462


AIMS:
To characterise the transfer of venlafaxine (V) and its O-desmethyl
metabolite (ODV) into human milk by measuring milk/plasma (M/P) ratio, and
to estimate the likely dose received by a breast-fed infant.

METHODS:
Milk and plasma samples were collected from three lactating women who were
taking venlafaxine for depression, and were at steady-state. In two of the
patients, venous blood and milk samples were collected 0, 1, 2, 3, 4, 6, 8
and 12 h post dose, while in the third patient a single pair of blood and
milk samples was obtained 0.83 h post dose. A plasma sample was obtained
from each of their infants. V and ODV were measured in plasma and milk by
high performance liquid chromatography. M/P was calculated and infant dose
estimated as drug concentration in milk x a milk intake of 0.15 l kg(-1)
day(-1), relative to the weight-adjusted maternal dose.

RESULTS:
Mean M/P for V was 4.1 (range 2.8-4.8) and 3.1 for ODV (range 2.8-3.8). The
mean total infant dose (as V equivalents) was 7.6% (range 4.7-9.2%) of the
maternal weight-adjusted dose, with approximately equal amounts of V (3.5%)
and ODV (4.1%) in the dose. ODV (median 100 microg I(-1)) was detected in
the plasma of all three infants. The infants were healthy and showed no
acute adverse effects.

CONCLUSIONS:
These preliminary data show that the total dose of V and ODV ingested by
breast-fed infants can be as high as 9.2% of maternal intake. Moreover there
were measurable concentrations of ODV in the infants' plasma. We recommend
that exposed infants should be observed closely.

Publication Types:
? Clinical trial

PMID: 9643618, UI: 98305771